Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo

J Frantzias, J G Logan, P Mollat, A Sparatore, P Del Soldato, S H Ralston, A I Idris

Research output: Contribution to journalArticlepeer-review

Abstract

Hydrogen sulphide (H(2)S) and prostaglandins are both involved in inflammation, cancer and bone turnover, and non-steroidal anti-inflammatory drugs (NSAIDs) and H(2)S donors exhibit anti-inflammatory and anti-tumour properties. H(2)S-releasing diclofenac (S-DCF) derivatives are a novel class of NSAIDs combining the properties of a H(2)S donor with those of a conventional NSAID.
Original languageEnglish
Pages (from-to)1914-25
Number of pages12
JournalBritish Journal of Pharmacology
Volume165
Issue number6
DOIs
Publication statusPublished - 2012

Fingerprint Dive into the research topics of 'Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo'. Together they form a unique fingerprint.

Cite this